1-Phenyl-2-propylaminopentane (PPAP), also known as 'α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306', is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
1-Phenyl-2-propylaminopentane (PPAP), also known as 'α,N-dipropylphenethylamine (DPPEA) and by the developmental code name MK-306', is an experimental drug related to selegiline which acts as a catecholaminergic activity enhancer (CAE).
PPAP is a CAE and enhances the nerve impulse propagation-mediated release of norepinephrine and dopamine. It produces psychostimulant-like effects in animals. In 2025, it was discovered that PPAP is a potent catecholamine reuptake inhibitor, including of dopamine and to a lesser extent of norepinephrine. The drug is a phenethylamine and amphetamine derivative and was derived via structural modification of selegiline.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).